On Thursday, Fujifilm Healthcare Americas announced the commercialization of two novel endoscopic imaging technologies: CAD EYE®, an AI detection system for endoscopic imaging that enables real-time detection of colonic mucosal lesions during colonoscopy procedures, and SCALE EYE®, an imaging technology for measuring colonic lesions.
Since receiving 510(k) clearance for CAD EYE in March, the technology has been installed at five clinical sites in the U.S., including community hospitals and academic medical centers.
Most Read on Medical Design & Development:
- Will AI Replace Doctors Who Read X-rays, or Make Them Better?
- FDA Expands Warning for Imported Plastic Syringes from China
- Danaher Launches Collaboration with Johns Hopkins University
- Why Your Manufacturer Belongs on the Design Team
According to Jason Samarasena, MD, gastroenterologist with UCI Health, Fujifilm is addressing several key challenges for doctors and working alongside endoscopists to elevate quality standards in colonoscopy.
Both CAD Eye, which leverages AI for polyp detection, and SCALE Eye, a novel real-time polyp measurement solution, are integrated with Fujifilm's ELUXEO platform, a next-generation endoscopic video imaging system.
Click here to subscribe to our daily newsletter featuring breaking medical device industry news.
